Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Gentile

Showing results (191-200 of 313) with videos related to

Pageof 32
Sort By:
American Journal of Hematology|December 23, 2016
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trialsMassimo Gentile, Valeria Magarotto, Massimo Offidani, et al.
British Journal of Haematology|May 15, 2009
Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemiaFortunato Morabito, Giovanna Cutrona, Massimo Gentile, et al.
International Journal of Molecular Sciences|February 13, 2026
Intraclonal Enrichment of IL-23 Receptor Complex Expression in the Proliferative Fraction of Chronic Lymphocytic LeukemiaMartina Cardillo, Fabiana Ferrero, Nadia Bertola, et al.
American Journal of Hematology|March 16, 2017
Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphomaFrancesca Romana Mauro, Piero Galieni, Alessandra Tedeschi, et al.
Hematological Oncology|July 6, 2022
Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplantCirino Botta, Emilia Gigliotta, Bruno Paiva, et al.
Annals of Hematology|August 3, 2017
Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control studyArtur Jurczyszyn, Alessandro Gozzetti, Joanna Gdula-Argasińska, et al.
Journal of Translational Medicine|February 27, 2024
Targeting of mitochondrial fission through natural flavanones elicits anti-myeloma activityRoberta Torcasio, Maria Eugenia Gallo Cantafio, Claudia Veneziano, et al.
Frontiers in Oncology|March 25, 2021
Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life SurveyUros Markovic, Alessandra Romano, Vittorio Del Fabro, et al.
Leukemia & Lymphoma|December 16, 2015
Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter studyAnnalisa Arcari, Annalisa Chiappella, Michele Spina, et al.
American Journal of Hematology|April 9, 2014
Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL studyMassimo Gentile, Giovanna Cutrona, Laura Mosca, et al.
Pageof 32

Showing results (191-200 of 313) with videos related to

Sort By:
Pageof 32
American Journal of Hematology|December 23, 2016
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trialsMassimo Gentile, Valeria Magarotto, Massimo Offidani, et al.
British Journal of Haematology|May 15, 2009
Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemiaFortunato Morabito, Giovanna Cutrona, Massimo Gentile, et al.
International Journal of Molecular Sciences|February 13, 2026
Intraclonal Enrichment of IL-23 Receptor Complex Expression in the Proliferative Fraction of Chronic Lymphocytic LeukemiaMartina Cardillo, Fabiana Ferrero, Nadia Bertola, et al.
American Journal of Hematology|March 16, 2017
Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphomaFrancesca Romana Mauro, Piero Galieni, Alessandra Tedeschi, et al.
Hematological Oncology|July 6, 2022
Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplantCirino Botta, Emilia Gigliotta, Bruno Paiva, et al.
Annals of Hematology|August 3, 2017
Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control studyArtur Jurczyszyn, Alessandro Gozzetti, Joanna Gdula-Argasińska, et al.
Journal of Translational Medicine|February 27, 2024
Targeting of mitochondrial fission through natural flavanones elicits anti-myeloma activityRoberta Torcasio, Maria Eugenia Gallo Cantafio, Claudia Veneziano, et al.
Frontiers in Oncology|March 25, 2021
Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life SurveyUros Markovic, Alessandra Romano, Vittorio Del Fabro, et al.
Leukemia & Lymphoma|December 16, 2015
Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter studyAnnalisa Arcari, Annalisa Chiappella, Michele Spina, et al.
American Journal of Hematology|April 9, 2014
Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL studyMassimo Gentile, Giovanna Cutrona, Laura Mosca, et al.
Pageof 32